Amylyx Pharmaceuticals IncNASDAQ:AMLX
- LAST PRICE1.8500
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.8200/ 10
- Ask / Lots1.8500/ 1
- Open / Previous Close0.0000 / 1.8500
- Day Range---
- 52 Week Range
- Volume2,240
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AMLX |
|---|---|---|
| 09:32 ET | 23837 | 1.82 |
| 09:34 ET | 17162 | 1.83 |
| 09:36 ET | 1195 | 1.825 |
| 09:38 ET | 828 | 1.82 |
| 09:39 ET | 2000 | 1.825 |
| 09:41 ET | 18119 | 1.825 |
| 09:43 ET | 300 | 1.82 |
| 09:45 ET | 623 | 1.82 |
| 09:48 ET | 300 | 1.825 |
| 09:50 ET | 6400 | 1.825 |
| 09:52 ET | 936 | 1.825 |
| 09:54 ET | 13250 | 1.825 |
| 09:56 ET | 12770 | 1.81 |
| 09:57 ET | 2663 | 1.815 |
| 09:59 ET | 12306 | 1.805 |
| 10:01 ET | 8508 | 1.82 |
| 10:03 ET | 1000 | 1.8194 |
| 10:06 ET | 17426 | 1.82 |
| 10:08 ET | 100 | 1.82 |
| 10:10 ET | 1000 | 1.815 |
| 10:12 ET | 896 | 1.8193 |
| 10:14 ET | 200 | 1.82 |
| 10:15 ET | 700 | 1.8131 |
| 10:17 ET | 12816 | 1.82 |
| 10:19 ET | 2500 | 1.82 |
| 10:21 ET | 2416 | 1.825 |
| 10:24 ET | 2520 | 1.825 |
| 10:26 ET | 100 | 1.825 |
| 10:28 ET | 600 | 1.825 |
| 10:30 ET | 1550 | 1.83 |
| 10:32 ET | 225 | 1.825 |
| 10:33 ET | 1177 | 1.825 |
| 10:35 ET | 136 | 1.825 |
| 10:37 ET | 200 | 1.825 |
| 10:39 ET | 3163 | 1.82 |
| 10:42 ET | 1088 | 1.82 |
| 10:44 ET | 300 | 1.825 |
| 10:48 ET | 734 | 1.825 |
| 10:50 ET | 400 | 1.825 |
| 10:51 ET | 8639 | 1.815 |
| 10:53 ET | 180 | 1.815 |
| 10:55 ET | 2084 | 1.82 |
| 10:57 ET | 500 | 1.82 |
| 11:00 ET | 251 | 1.82 |
| 11:02 ET | 1700 | 1.81 |
| 11:04 ET | 4674 | 1.815 |
| 11:06 ET | 949 | 1.815 |
| 11:08 ET | 2200 | 1.82 |
| 11:09 ET | 1550 | 1.815 |
| 11:11 ET | 172016 | 1.84 |
| 11:13 ET | 2603 | 1.835 |
| 11:15 ET | 1300 | 1.835 |
| 11:18 ET | 6936 | 1.8301 |
| 11:20 ET | 400 | 1.83 |
| 11:22 ET | 3214 | 1.83 |
| 11:24 ET | 1000 | 1.835 |
| 11:26 ET | 428 | 1.835 |
| 11:27 ET | 1200 | 1.835 |
| 11:29 ET | 1000 | 1.835 |
| 11:31 ET | 24979 | 1.83 |
| 11:33 ET | 400 | 1.835 |
| 11:36 ET | 3419 | 1.83 |
| 11:38 ET | 100 | 1.835 |
| 11:40 ET | 330 | 1.84 |
| 11:42 ET | 600 | 1.83 |
| 11:44 ET | 13552 | 1.8257 |
| 11:45 ET | 200 | 1.825 |
| 11:47 ET | 300 | 1.825 |
| 11:49 ET | 300 | 1.825 |
| 11:51 ET | 200 | 1.82 |
| 11:54 ET | 3340 | 1.825 |
| 11:56 ET | 400 | 1.825 |
| 11:58 ET | 500 | 1.825 |
| 12:00 ET | 400 | 1.825 |
| 12:02 ET | 2887 | 1.825 |
| 12:03 ET | 6800 | 1.825 |
| 12:05 ET | 240 | 1.8238 |
| 12:07 ET | 1109 | 1.825 |
| 12:09 ET | 200 | 1.825 |
| 12:12 ET | 500 | 1.825 |
| 12:14 ET | 4164 | 1.825 |
| 12:16 ET | 1188 | 1.825 |
| 12:18 ET | 1301 | 1.825 |
| 12:20 ET | 1195 | 1.825 |
| 12:21 ET | 474 | 1.83 |
| 12:23 ET | 1288 | 1.825 |
| 12:25 ET | 300 | 1.825 |
| 12:27 ET | 200 | 1.83 |
| 12:30 ET | 2134 | 1.83 |
| 12:32 ET | 1781 | 1.825 |
| 12:34 ET | 1700 | 1.825 |
| 12:36 ET | 29875 | 1.825 |
| 12:38 ET | 103727 | 1.835 |
| 12:39 ET | 17860 | 1.83 |
| 12:41 ET | 18201 | 1.855 |
| 12:43 ET | 90697 | 1.85 |
| 12:45 ET | 1063 | 1.855 |
| 12:48 ET | 2989 | 1.855 |
| 12:50 ET | 4453 | 1.855 |
| 12:52 ET | 5660 | 1.86 |
| 12:54 ET | 2368 | 1.855 |
| 12:56 ET | 12819 | 1.84 |
| 12:57 ET | 1080 | 1.845 |
| 12:59 ET | 4003 | 1.848 |
| 01:01 ET | 3878 | 1.85 |
| 01:03 ET | 65525 | 1.845 |
| 01:06 ET | 4875 | 1.845 |
| 01:08 ET | 2300 | 1.85 |
| 01:10 ET | 21411 | 1.85 |
| 01:12 ET | 1913 | 1.85 |
| 01:14 ET | 1509 | 1.855 |
| 01:15 ET | 31377 | 1.855 |
| 01:17 ET | 300 | 1.86 |
| 01:19 ET | 100 | 1.86 |
| 01:21 ET | 24341 | 1.845 |
| 01:24 ET | 54154 | 1.85 |
| 01:26 ET | 900 | 1.85 |
| 01:28 ET | 500 | 1.86 |
| 01:30 ET | 3389 | 1.86 |
| 01:32 ET | 2100 | 1.855 |
| 01:33 ET | 19107 | 1.86 |
| 01:35 ET | 8187 | 1.865 |
| 01:37 ET | 5809 | 1.865 |
| 01:39 ET | 6000 | 1.8693 |
| 01:42 ET | 1741 | 1.865 |
| 01:44 ET | 4311 | 1.865 |
| 01:46 ET | 9932 | 1.865 |
| 01:48 ET | 1150 | 1.865 |
| 01:50 ET | 1425 | 1.865 |
| 01:51 ET | 10364 | 1.86 |
| 01:53 ET | 2393 | 1.86 |
| 01:55 ET | 3749 | 1.86 |
| 01:57 ET | 700 | 1.87 |
| 02:00 ET | 700 | 1.865 |
| 02:02 ET | 600 | 1.86 |
| 02:04 ET | 11163 | 1.855 |
| 02:06 ET | 300 | 1.855 |
| 02:08 ET | 101448 | 1.86 |
| 02:09 ET | 1468 | 1.86 |
| 02:11 ET | 900 | 1.86 |
| 02:13 ET | 2800 | 1.86 |
| 02:15 ET | 12015 | 1.8507 |
| 02:18 ET | 600 | 1.86 |
| 02:20 ET | 600 | 1.855 |
| 02:22 ET | 3866 | 1.86 |
| 02:24 ET | 14248 | 1.86 |
| 02:26 ET | 2399 | 1.865 |
| 02:27 ET | 6200 | 1.865 |
| 02:29 ET | 664 | 1.87 |
| 02:31 ET | 3990 | 1.87 |
| 02:33 ET | 1525 | 1.865 |
| 02:36 ET | 1500 | 1.87 |
| 02:38 ET | 1166 | 1.87 |
| 02:40 ET | 7466 | 1.87 |
| 02:42 ET | 9048 | 1.87 |
| 02:44 ET | 5624 | 1.875 |
| 02:45 ET | 2849 | 1.88 |
| 02:47 ET | 1600 | 1.88 |
| 02:49 ET | 1500 | 1.875 |
| 02:51 ET | 2559 | 1.88 |
| 02:54 ET | 4100 | 1.88 |
| 02:56 ET | 5446 | 1.88 |
| 02:58 ET | 3425 | 1.875 |
| 03:00 ET | 2991 | 1.88 |
| 03:02 ET | 7167 | 1.88 |
| 03:03 ET | 4545 | 1.88 |
| 03:05 ET | 2975 | 1.88 |
| 03:07 ET | 55196 | 1.87 |
| 03:09 ET | 16200 | 1.875 |
| 03:12 ET | 3563 | 1.875 |
| 03:14 ET | 886 | 1.875 |
| 03:16 ET | 1705 | 1.88 |
| 03:18 ET | 2125 | 1.875 |
| 03:20 ET | 1925 | 1.875 |
| 03:21 ET | 82684 | 1.885 |
| 03:23 ET | 1800 | 1.89 |
| 03:25 ET | 1536 | 1.89 |
| 03:27 ET | 18065 | 1.89 |
| 03:30 ET | 3642 | 1.885 |
| 03:32 ET | 9218 | 1.885 |
| 03:34 ET | 3313 | 1.88 |
| 03:36 ET | 7200 | 1.885 |
| 03:38 ET | 31183 | 1.875 |
| 03:39 ET | 1640 | 1.875 |
| 03:41 ET | 1625 | 1.875 |
| 03:43 ET | 1712 | 1.875 |
| 03:45 ET | 3261 | 1.88 |
| 03:48 ET | 4373 | 1.88 |
| 03:50 ET | 4498 | 1.88 |
| 03:52 ET | 51957 | 1.86 |
| 03:54 ET | 5356 | 1.86 |
| 03:56 ET | 8202 | 1.865 |
| 03:57 ET | 52381 | 1.85 |
| 03:59 ET | 407333 | 1.85 |
Jun 24, 2024
DJ Amylyx Pharmaceuticals Price Target Maintained With a $8.00/Share by HC Wainwright & Co., from 6:33AM ET on Monday Jun 24, 2024 by Dow Jones
6:33AM ET on Monday Jun 24, 2024 by Dow Jones
Jun 4, 2024
Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference, from 9:00AM ET on Tuesday Jun 04, 2024 by Dow Jones
9:00AM ET on Tuesday Jun 04, 2024 by Dow Jones
May 31, 2024
Lifshitz Law PLLC Announces Investigations of Cassava Sciences, Inc. (NASDAQ: SAVA), iRhythm Technologies, Inc. (NASDAQ: IRTC), Xponential Fitness, Inc. (NYSE: XPOF), and Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), from 11:01PM ET on Friday May 31, 2024 by Dow Jones
11:01PM ET on Friday May 31, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Amylyx Pharmaceuticals Inc | 125.8M | -1.7x | --- |
Organogenesis Holdings Inc | 331.4M | 57.5x | --- |
Amarin Corporation PLC | 299.2M | -5.7x | --- |
Coherus BioSciences Inc | 181.3M | -2.0x | --- |
Sinovac Biotech Ltd | 639.9M | -6.0x | --- |
Puma Biotechnology Inc | 142.8M | 9.2x | --- |
Company Information
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate, AMX0035 (sodium phenylbutyrate and taurursodiol, also known as ursodoxicoltaurine) for the treatment of amyotrophic lateral sclerosis (ALS). RELYVRIO (also known as AMX0035), an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol is approved to treat ALS in adults in the United States. AMX0035 is a dual unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). Its development of antisense oligonucleotides (ASOs), including lead ASO AMX0114, which targets calpain-2 (CAPN2), a gene encoding calcium-dependent proteolytic enzyme which has been implicated in the pathogenesis of ALS and other neurodegenerative diseases.
Contact Information
- Headquarters
- 43 THORNDIKE STREETCAMBRIDGE, MA, United States 02141
- Phone
- 617-682-0917
- Fax
- 302-636-5454
Executives
- Chair of the Board of Directors
- George Milne
- Co-Chief Executive Officer, Director
- Joshua Cohen
- Co-Chief Executive Officer, Director
- Justin Klee
- Chief Financial Officer
- James Frates
- Chief Legal Officer and General Counsel
- Gina Mazzariello
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $125.8M |
|---|---|
Revenue (TTM) | $398.0M |
Shares Outstanding | 68.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.07 |
Book Value | $6.40 |
P/E Ratio | -1.7x |
Price/Sales (TTM) | 0.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -20.42% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
